Functional analysis of RPS27 mutations and expression in melanoma

Floristán, Alfredo; Morales, Leah; Hanniford, Douglas; Martínez, Carlos Navarro; Castellano-Sanz, Elena; Dolgalev, Igor; Ulloa-Morales, Alejandro; Miera, Eleazar Vega-Saenz de; Moran, Una; Darvishian, Farbod; Osman, Iman; Kirchhoff, Tomas; Hernando, Eva

doi:10.1111/pcmr.12841

Cited by 16 publications

(21 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since mRNA expression does not necessarily reflect protein expression due to post-translational modification, we cannot exclude that there might be a correlation of RPS27 protein expression with the patients' clinical course. Nevertheless, TCGA data largely confirmed our findings, except for a recent report analyzing the TCGA dataset showing that patients diagnosed with low-grade gliomas and high RPS27 expression had a better prognosis than those patients with low expression [39]. Having a second look at our Kaplan-Meier analysis, we see a similar trend for the long-term survivors in our WHO grade II/III cohort.…”

Section: Discussionsupporting

confidence: 88%

Ribosomal Protein S27/Metallopanstimulin-1 (RPS27) in Glioma—A New Disease Biomarker?

Keßler

Schmitt

Salvador

et al. 2020

Cancers

View full text Add to dashboard Cite

Despite its significant overexpression in several malignant neoplasms, the expression of RPS27 in the central nervous system (CNS) is widely unknown. We identified the cell types expressing RPS27 in the CNS under normal and disease conditions. We acquired specimens of healthy brain (NB), adult pilocytic astrocytoma (PA) World Health Organization (WHO) grade I, anaplastic PA WHO grade III, gliomas WHO grade II/III with or without isocitrate dehydrogenase (IDH) mutation, and glioblastoma multiforme (GBM). RPS27 protein expression was examined by immunohistochemistry and double-fluorescence staining and its mRNA expression quantified by RT-PCR. Patients’ clinical and tumor characteristics were collected retrospectively. RPS27 protein was specifically expressed in tumor cells and neurons, but not in healthy astrocytes. In tumor tissue, most macrophages were positive, while this was rarely the case in inflamed tissue. Compared to NB, RPS27 mRNA was in mean 6.2- and 8.8-fold enhanced in gliomas WHO grade II/III with (p < 0.01) and without IDH mutation (p = 0.01), respectively. GBM displayed a 4.6-fold increased mean expression (p = 0.02). Although RPS27 expression levels did not affect the patients’ survival, their association with tumor cells and tumor-associated macrophages provides a rationale for a future investigation of a potential function during gliomagenesis and tumor immune response.

show abstract

Section: Discussionsupporting

confidence: 88%

Ribosomal Protein S27/Metallopanstimulin-1 (RPS27) in Glioma—A New Disease Biomarker?

Keßler

Schmitt

Salvador

et al. 2020

Cancers

View full text Add to dashboard Cite

show abstract

“…On the other hand, we associate the bimodal expression pattern with prognosis. To our knowledge, only [11] have associated the bimodal expression pattern of RPS27 with clinical outcome in several tumor types, a gene also observed in our data. This makes our analysis the first one, to our knowledge, to explore the association between the modes of gene expression distribution with prognosis in a genome-wide context.…”

Section: Discussionsupporting

confidence: 70%

“…It is made available under a preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in The copyright holder for this this version posted December 21, 2020. ; https://doi.org/10.1101/2020.12.21.423759 doi: bioRxiv preprint bimodal expression pattern in muscle tissue. Other genes include RPS27, found by [11] to have bimodal expression in several tumor types, and USP9AY, found to show bimodality in endometrium [26]. Interestingly, among the genes with bimodality in more than one tumor type, 12 are mapped to the Y chromosome (p<10 -5 ), an unexpected observation due to the low gene density in this chromosome.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A new genome-wide method to identify genes with bimodal gene expression

Justino

Reis²,

Fonseca³

et al. 2020

Preprint

View full text Add to dashboard Cite

A new method is presented to detect bimodality in gene expression data using the Gaussian Mixture Models to cluster samples in each mode. We have used the method to search for bimodal genes in data from 25 tumor types available from The Cancer Genome Atlas. The method identified 554 genes with bimodal gene expression, of which 46 were identified in more than one cancer type. To further illustrate the impact of the method, we show that 96 out of the 554 genes with bimodal expression patterns presented different prognosis when patients belonging to the two expression peaks are compared. The software to execute the method and the corresponding documentation are available at https://github.com/LabBiosystemUFRN/Bimodality_Genes.

show abstract

“…Overexpression of RPS14 can inhibit Rb phosphorylation and induce cell cycle arrest and aging, which may be related to cancer treatment [ 34 ]. Also, low expression of RPS27 is associated with poor clinical prognosis in melanoma [ 35 ]. RPL11, affecting osteosarcoma malignant phenotype, may be a new prognostic markers of osteosarcoma survival [ 36 ].…”

Section: Discussionmentioning

confidence: 99%

Identification of ribosomal protein family in triple-negative breast cancer by bioinformatics analysis

et al. 2021

View full text Add to dashboard Cite

Triple-negative breast cancer (TNBC) accounts for ∼20% of all breast cancer (BC) cases. The management of TNBC represents a challenge due to its worse prognosis, heterogeneity and lack of targeted therapy. Moreover, its mechanisms are not fully clear. The aim of the study is to identify crucial genes between TNBC and non-TNBC for underlying targets for diagnostic and therapeutic methods of TNBC. The differentially expressed genes (DEGs) between TNBC and non-TNBC were selected from the Gene Expression Omnibus (GEO) database after the integrated analysis of two datasets (GSE65194 and GSE76124). Then Gene ontology (GO) and KEGG analysis were performed by DAVID database, protein–protein interaction (PPI) of DEGs was constructed by Search Tool for the Retrieval of Reciprocity Genes (STRING) database. Furthermore, centrality analysis and module analysis were carried out by Cytoscape to analyze the TNBC-related PPI. Subsequently, overall survival (OS) analysis was performed by GEPIA. Finally, the expressions of these key genes in TNBC and non-TNBC tissues were tested by qRT-PCR. The results showed that 955 DEGs were obtained, which were mainly enriched in ribosome, ribosomal subunit, and so on. Moreover, 19 candidate genes were focused on by centrality analysis and module analysis. Furthermore, we found the low expressions of ribosomal protein S9 (RPS9), ribosomal protein S14 (RPS14), ribosomal protein S27 (RPS27), ribosomal protein L11 (RPL11) and ribosomal protein L14 (RPL14) were related to a poor OS in BC patients. Additionally, qRT-PCR results suggested that these five genes were notably down-regulated in TNBC tissues. In summary, the present study suggests that ribosomal proteins are related to TNBC, and they may play an important role in the diagnosis, treatment and prognosis of TNBC.

show abstract

Functional analysis of RPS27 mutations and expression in melanoma

Cited by 16 publications

References 34 publications

Ribosomal Protein S27/Metallopanstimulin-1 (RPS27) in Glioma—A New Disease Biomarker?

Ribosomal Protein S27/Metallopanstimulin-1 (RPS27) in Glioma—A New Disease Biomarker?

A new genome-wide method to identify genes with bimodal gene expression

Identification of ribosomal protein family in triple-negative breast cancer by bioinformatics analysis

Contact Info

Product

Resources

About